A new technology for targeting proteins inside cells

No Images? Click here

Alphabody Therapeutics
 
 

A new technology for targeting proteins inside cells

 

In the September issue of MedNous Dr Mark Vaeck, CEO of Complix, provides an update on the recent progress achieved by the Company.

"Over the past decade our Belgium-based company Complix NV has developed a preclinical portfolio of biologics directed against intracellular targets that we believe represents a novel approach for treating cancer and other important diseases. In our lead programme we are currently selecting a development candidate with a view to bringing our first product into the clinic. In this article we explain how we arrived at this point in the company’s development."

 

The article was written by Dr Mark Vaeck, co-founder and Chief Executive Officer of Complix NV.

READ THE FULL ARTICLE >
 

Thank you for your interest.

Kind regards,
The Complix team

 
 
 

Press releases, events and news from Complix

Stay informed about Complix, and discover valuable information about our products and technology.

VISIT COMPLIX.COM >
 
 
Complix NV
Technologiepark 4
9052 Zwijnaarde (Ghent)
Belgium
Phone: +32 (0)9 261 69 40
​The new European privacy regulations (GDPR) came into effect on 25 May 2018, they protect your privacy and give you control over the use of your personal data. When we have news to report about our research or collaborations, we inform you via our News Releases. We will continue to send you emails of which we are convinced that they are interesting to you. If you prefer no longer to receive News Releases from Complix nv, you can unsubscribe here:
  Like 
  Tweet 
  Share 
  Forward 
Preferences  |  Unsubscribe